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FIGURE 1 The Annual Stroke Risk Stratiﬁed With CHA2DS2-VASc Scores
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The annual stroke risk is stratiﬁed with CHA2DS2-VASc scores from different epidemiological series: United States (4), Sweden (2), Denmark (3),
Taiwan (1), and Hong Kong (5).
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1603transient ischemic strokes in Chinese. A similar
observation has been made in other Asian countries.
Unfortunately, little is reported about the subtypes of
stroke in most registries or even in randomized
controlled trials. Notwithstanding, the burning
question remains whether clinicians should initiate
long-term anticoagulation therapy in Chinese pa-
tients with AF and a CHA2DS2-VASc score of 0. It is
very tempting to do so, given the excellent safety
proﬁle of NOACs that has resulted in a lowering of the
threshold for initiating NOAC treatment to an annual
stroke risk of 1%/year. Nonetheless, it lacks support
from randomized placebo-controlled trials, the gold
standard to demonstrate treatment effects, specif-
ically targeted at this presumably “low-risk” popula-
tion. Further research is vital to determine the risk of
cardioembolic stroke as well as other subtypes of
stroke amongst Chinese patients with AF and to
develop new stroke risk models that accurately
stratify such risks.*Chung-Wah Siu, MD
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1401–8.REPLY: One More “C” for
CHA2DS2-VASc ScoreWe thank Dr. Siu for his comments regarding our
recently published paper (1) about the usefulness of
the CHA2DS2-VASc score for reﬁning stroke risk
stratiﬁcation among patients with atrial ﬁbrillation
(AF) having an ATRIA (Anticoagulation and Risk
Factors in Atrial Fibrillation) score of 0 to 5. We agree
that the risk of ischemic stroke for Chinese AF pa-
tients with a CHA2DS2-VASc score of 0 is higher than
that of Caucasians. However, it does not mean that
non-vitamin K antagonist oral anticoagulants
(NOACs) should be routinely prescribed for these
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1604patients. Our previous study demonstrated that the
risk of ischemic stroke for AF and non-AF patients
with a CHA2DS2-VASc score of 0 was similar (2).
Therefore, the better way to reduce stroke risk among
these patients is to try to identify “novel” risk factors
that were not included in the CHA2DS2-VASc scheme
for these “low-risk” patients. For example, hyper-
uricemia, deﬁned as having at least 1 episode of gout
attack necessitating long-term treatment with uric
acid–lowering agents, was shown to be an important
risk factor of ischemic stroke for AF patients in
Taiwan (3). Interestingly, hyperuricemia was associ-
ated with a higher risk of ischemic stroke even among
patients with a CHA2DS2-VASc score of 0, suggesting
that it may reﬁne stroke risk stratiﬁcation in this
“low-risk” population.
It should also be noted that the occurrence of
ischemic stroke in AF was not all caused by cardiac
thromboembolism, and atherosclerosis or thrombosis
of the cerebral artery is another possible reason. In
the Taiwan Stroke Registry studying 22,642 patients
with acute ischemic stroke, history of AF was noted in
16.5% of patients (4). However, there was only 10.9%
of these patients whose type of stroke was classiﬁed
as “cardioembolism” by diagnostic criteria (5). It may
suggest that around one-third of stroke in AF patients
may not result from cardiac thromboembolism.
Therefore, whether the use of oral anticoagulants can
provide beneﬁts exceeding the risk of major bleeding
for AF patients with a CHA2DS2-VASc of 0 remainsvery uncertain. We welcome continued efforts and
discussions on this issue to improve the quality of
care for AF patients regarding stroke risk reduction.Tze-Fan Chao, MD
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